Prevention · Screening · Early detection
Cancer Screening: Who Needs Which Test?
Screening tests people without symptoms. The right choice depends on age, organs, risk, previous results and whether follow-up treatment is feasible.
Chapter 7 of 16
Choose a chapter
Key facts
- More tests do not automatically mean better prevention.
- Symptoms need diagnostic assessment, even after a normal screening result.
- A screening programme includes follow-up, not just the first test.
From information to action
| Action | How to use it |
|---|---|
| Bring prior screening reports and dates, not just a recollection of normal results. | Discuss feasibility and any relevant medical conditions with your healthcare team. |
| Ask which guideline and risk group apply to you. | Discuss feasibility and any relevant medical conditions with your healthcare team. |
| Arrange follow-up before choosing a test; do not ignore an abnormal report. | Discuss feasibility and any relevant medical conditions with your healthcare team. |
| Report symptoms rather than waiting for a screening appointment. | Discuss feasibility and any relevant medical conditions with your healthcare team. |
Choose the right next step
- New or concerning symptoms? Arrange diagnostic assessment. Severe bleeding, breathlessness or new neurological weakness needs urgent care.
- No symptoms, but previous cancer, precancer or increased inherited risk? Ask for an individual surveillance plan; average-risk intervals may not apply.
- No such history? Use this chapter to discuss prevention and, where appropriate, age- and test-specific screening. Lifestyle exposures alone do not establish eligibility for every test.
- After testing: Collect the result, complete any referral, and record the next review date. A normal screen does not explain a later symptom.
Screening, early diagnosis and diagnostic tests
Screening looks for disease or precancer before symptoms. Early diagnosis means acting promptly on symptoms. Diagnostic tests investigate a symptom or abnormal finding and may include imaging or biopsy. A positive screening result is not a confirmed cancer diagnosis; a negative result does not exclude all cancers or future disease.
Average risk versus high risk
Average risk generally excludes a relevant inherited syndrome, strong family history, previous cancer or important precancer, and certain chronic diseases or treatment exposures. High-risk people may need earlier, more frequent or different tests. After an abnormal result, the next test is follow-up or surveillance rather than a return to an average-risk schedule.
Understanding benefit and harm
Screening can reduce deaths for certain cancers and can prevent some cancers by finding treatable precursors. False positives cause anxiety and further tests; false negatives can delay diagnosis. Overdiagnosis means detecting a cancer that would never cause harm during a person’s lifetime. Treatment of that cancer can still cause side effects. Imaging radiation, bowel preparation, biopsy bleeding and procedure complications also matter.
How to decide and when to stop
Discuss what a test can find, how often to repeat it, costs and what happens if it is abnormal. Screening benefits often take years to appear. Poor health, limited life expectancy or inability to undergo investigation or treatment may change the balance. Stopping criteria vary by cancer and prior screening; there is no single stopping age for every test.
Tests not suitable as universal screening
Routine whole-body PET-CT, tumour-marker panels and whole-body MRI are not recommended for asymptomatic average-risk adults. Specialist MRI surveillance in defined hereditary syndromes is a different setting. Multicancer blood tests are evolving and should not replace established programmes; accuracy alone does not establish a mortality benefit. A disease-specific validated blood test is also not equivalent to a universal cancer test.
India and oral cancer screening
India’s national approach focuses on oral, breast and cervical screening through primary care. Ask about oral examination particularly with tobacco or areca use. International mammography, colorectal, lung and prostate recommendations are useful discussion frameworks, not automatic Indian national policies. A high-quality service must provide results, referral and treatment access rather than sell a test package alone.
Cancers without routine average-risk screening
USPSTF advises against routine ovarian screening in asymptomatic people without a known high-risk hereditary syndrome: CA-125 and transvaginal ultrasound have not shown a mortality benefit and may lead to unnecessary surgery. It also recommends against pancreatic screening in asymptomatic average-risk adults and thyroid screening in asymptomatic adults. These recommendations do not replace assessment of symptoms or specialist surveillance for defined inherited risks.
What test accuracy means
Sensitivity describes how often a test detects the target disease when it is present; specificity describes how often it is negative when disease is absent. The chance that a positive result represents disease also depends on how common the disease is in the tested population. Accuracy varies by assay, threshold, age, specimen quality and setting. A single accuracy percentage cannot describe every screening test or prove that screening reduces deaths.
Practical steps
- Bring prior screening reports and dates, not just a recollection of normal results.
- Ask which guideline and risk group apply to you.
- Arrange follow-up before choosing a test; do not ignore an abnormal report.
- Report symptoms rather than waiting for a screening appointment.
Myth and fact
An annual full-body scan is the best screening plan.
False. Unselected scans can cause false alarms, radiation exposure and unnecessary procedures without proven overall benefit.
Frequently asked questions
Do normal tumour markers rule out cancer?
No. Most markers are unsuitable for general screening and may be normal despite cancer.
Does an abnormal test mean cancer?
No. It means the result needs the appropriate clinical assessment or follow-up.
Continue learning
Sources and guideline context
- NCI — Cancer screening overview
PDQ living review
- NCI — Questions about multicancer detection tests
Living resource
- USPSTF — Breast cancer screening
30 April 2024; B recommendation
- USPSTF — Colorectal cancer screening
18 May 2021; A/B/C by age
- USPSTF — Lung cancer screening
9 March 2021; B recommendation
- USPSTF — Prostate cancer screening
8 May 2018 final; C at 55–69, D at 70+
- MoHFW — Operational Framework: Management of Common Cancers
2016 operational framework
- USPSTF — Ovarian cancer screening
13 February 2018; against routine screening
- USPSTF — Pancreatic cancer screening
6 August 2019; average-risk asymptomatic adults
- USPSTF — Thyroid cancer screening
9 May 2017; against screening asymptomatic adults